Overage | Horse Racing Free Tips

Jonathan Wong Still Searching For First Win In Louisiana

Trainer Jonathan Wong, who was hit with a two-year suspension by the Horseracing Integrity and Welfare Unit (HIWU) for a metformin positive, has resurfaced in Louisiana, where he has 15 horses at a private training center but has yet to visit the winner's circle. Wong sent out his first starter in Louisiana on Feb. 13. But the same trainer who had one of the biggest stables in Northern California has struggled there, sending out just five horses without a winner.

The plaintiff states of Louisiana and West Virginia won a preliminary injunction in federal court in July that will keep the Horseracing Integrity and Safety Act (HISA) Authority's rules from being implemented in those two states until a lawsuit challenging the constitutionality of HISA gets decided in full. Because he was not under a suspension issued by the Louisiana Racing Commission, Wong is being allowed to compete in the Bayou State.

Fair Grounds, which is owned by Churchill Downs Inc., did not give Wong any stalls but is allowing him to race.

Wong did not start a horse between July 1 and Feb. 13, when he sent out his first Louisiana runner, Desoto's War (Warrior's Reward). He has made just four starts at Fair Grounds and one at Delta Downs.

According to one of his owners, Brent Malmstrom, who is helping with Wong's legal fight, Wong had 141 horses before he was suspended.

Malmstrom and Wong have maintained that the trainer is innocent because the positive for the drug, which is used in humans to treat Type II diabetes, was a matter of environmental contamination.

Wong did not return phone calls from the TDN seeking comment.

“Jonathan Wong may have done some things in the past,” he said. “I can't speak to that. All I can speak to is this: he didn't do this. We don't know where the drug came from. It's odd that at point in time when all this happened almost half of the metformin positives occurred at Horseshoe Indianapolis.”

The horse that tested positive was Heaven and Earth (Gormley) and the positive was found after the filly won a June 1 maiden special weight race at Horseshoe Indianapolis.

Malmstrom acknowledged that this has been a difficult situation for Wong.

“The sad thing about this whole thing is that this cost him his marriage,” he said. “He's got four little children. He's doing whatever he can to survive as I, along with our lawyers, work on the legal side to figure out how to get relief.”

Malmstrom said that most of the horses Wong trained before the suspension have been sent to other trainers.

“He lost his entire business,” he said. “The bulk of the horses he has in Louisiana are mine. I don't turn my back on people when they're at their lowest point in life. Louisiana has been incredibly welcoming and we thank them. People deserve an opportunity to defend themselves and should have the right to earn a living while they are defending themselves. That's a fundamental thing.”

The Fair Grounds meet ends on March 24. Malmstrom said that after Fair Grounds closes Wong will focus on the meet at Evangeline Downs, which opens April 7.

Wong has been training since 2014 and has 1,194 career wins. His best year came in 2021, when he saddled 236 winners and won at a rate of 23%.

The post Jonathan Wong Still Searching For First Win In Louisiana appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Top Mid-Atlantic Trainer Farrior Faces Possible Suspension For Metformin

Trainer Anthony Farrior is facing a possible suspension after a horse he trained allegedly tested positive for the banned substance Metformin, according to a posting Friday on the Horseracing Integrity and Welfare Unit website.

His status is listed as “Pending: Provisional Suspension–Postponed.” Alexa Ravit, the director of communications & outreach for HIWU explained that the wording means, “that B Sample analysis has been requested following a positive A Sample result, so the implementation of the Provisional Suspension is postponed unless/until the B Sample comes back positive.”

Farrior will be allowed to train at least until the B sample is turned over to HIWU. If he is unable to beat the charges, he faces a suspension of up to two years and a fine of $25,000.

The infraction allegedly took place Nov. 5, 2023 at Laurel with the $10,000 claimer Geothermal (Gormley), who did not finish the race. According to the Equibase chart, Geothermal sustained an injury through the backstretch run, was pulled up entering the far turn and was vanned off. According to sources, the horse was euthanized, but the TDN has not been able to confirm that with its connections.

HIWU has penalized at least six trainers for Metformin positives, including Jonathan Wong, a top trainer on the Northern California circuit. In humans, Metformin is used to treat type 2 diabetes. Wong has said that he takes Metformin. The Federal Drug Administration has approved Metformin for use in humans but it is not officially approved for use in animals. Metformin has been used in horses to counteract the effects of equine metabolic syndrome, which is a disorder associated with inappropriate blood insulin levels and increased fat deposition.

Farrior's lawyer, Drew Mollica, said that to the best of his knowledge, Farrior does not take Metformin. However, he was adamant that in Farrior's case, the finding is a matter of environmental contamination.

“We are in the process of evaluating the evidence and intend to vigorously follow the evidence,” Mollica said. “We absolutely believe this is case of contamination. We are in the midst of fact finding and I think that it will be quite clear that Mr. Farrior is not liable for any wrongdoing. We are investigating any and all possibilities and eventualities. We firmly believe this is a case of contamination and when all the facts are in, it will be found that he was not liable or negligent on any manner.”

When asked what steps he would take if the B Sample came back positive, Mollica replied: “We'll cross that bridge when we get there. We ordered the B sample and are following the science. We believe that when we have all the science and the facts are in, we believe he will be exonerated.”

Farrior has been training since 2011 and has 837 wins from 3,708 starts. He is currently racing at Laurel, Charles Town and Mahoning Valley. He is leading the Charles Town standings with 134 wins on the year through Thursday. At Charles Town, he is winning with 25% of his starters.

The post Top Mid-Atlantic Trainer Farrior Faces Possible Suspension For Metformin appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Rice Hit With Bute Fine, Suspension; Lodges Appeal Just Before NYSGC To Rule On ‘Improper Practices’

Trainer Linda Rice has been suspended 14 days and fined $2,000 by the New York State Gaming Commission after a filly under her care returned a positive test for the non-steroidal anti-inflammatory drug phenylbutazone following a 9 1/2-length win as the 4-5 favorite at Aqueduct Racetrack more than eight months ago.

Rice has appealed the Sept. 28 ruling, so she has been granted a stay of those penalties pending a final resolution.

The NYSGC also made it public on Friday that Rice will be appearing before the commission for a separate matter when the board conducts its monthly meeting this coming Tuesday.

Rice's name appears on the just-released agenda for the Oct. 3 meeting for an adjudication of her “improper practices” case that has persisted at the commission level and in the New York courts for more than two years.

In 2021, the NYSGC fined Rice $50,000 and revoked her license for three years after investigating claims that Rice received favorable treatment from the New York Racing Association and that the racing office was releasing to her the names and past performances of horses that had already been entered in races, giving her an unfair advantage.

It was further alleged that Rice had paid racing officials in exchange for the information, a charge she denied. She did, however, admit to routinely giving members of the racing department, as well as the gate crew, Christmas presents.

On June 8, 2023, the New York Supreme Court Appellate Division ruled that the three-year banishment imposed by the NYSGC was “entirely unwarranted.”

But that same court also upheld the commission's determination that the “improper practices” rule had been violated, and ordered the matter back to the NYSGC to reassess the penalty “with the constraint that any reassessed penalty cannot contain a license revocation.”

Rice's Jan. 21, 2023, bute penalty was triggered by Afleet Arlene (Afleet Alex), who is owned by Winning Move Stable and has been unraced since that victory. A disqualification from the win and a purse redistribution from the $16,000 claimer ($15,400 winning purse) was mandated by the under-appeal ruling.

The ruling stated that the bute finding was “in excess of the quantitative threshold” of 0.3 mcg/ml in plasma.

The relatively long time that the NYSGC's drug-test findings linger behind the scenes prior to a ruling being issued has been an issue of concern in 2023, with some cases still resurfacing even after the Horseracing Integrity and Safety Act Authority took over as the sport's nationwide testing entity back on May 22.

Back on May 11, trainer Todd Pletcher was fined $1,000 and suspended 10 days after tests revealed that his trainee Forte (Violence) tested positive for meloxicam following a win in the GI Hopeful S. on Sept. 5, 2022, at Saratoga Race Course.

The length of the delay made headlines because in the interim between the Hopeful S. and the ruling, Forte won the GI Breeders' Cup Juvenile, was voted the Eclipse Award champion of his division, had won two other graded stakes, and was the favorite for the GI Kentucky Derby before being scratched the morning of the race with a right front foot bruise.

Another Pletcher trainee, Capensis (Tapit), triggered a bute finding in a Saratoga post-race test on July 30, 2022, but that ruling (14-day suspension, $2,000 fine) was not made public until 10 ½ months later, on June 11, 2023. Pletcher is currently appealing both cases.

In the ensuing debate over why New York's positives take so long to come to light, regulators have blamed trainers for “repeated procedural delays” in getting split samples tested, while horsemen have accused the commission of needlessly dragging out the process and not being responsive or timely in responding to scheduling requests.

At the May 22, 2023, NYSGC meeting, it was disclosed that three outstanding, pre-HISA Thoroughbred drug positives remained unadjudicated by the commission and were still lingering at various stages in the regulatory process.

When commissioner John Crotty asked what the timeline was for resolving those cases, NYSGC chairman Brian O'Dwyer told him that in light of the scrutiny related to the Forte delay, he suspected that the commission “will be very, very diligent in terms of making sure that those things are adjudicated much more promptly.”

It turns out that Rice's bute finding was one of those then-undisclosed cases. It took more than eight months from the date of the alleged violation until a ruling was issued.

The post Rice Hit With Bute Fine, Suspension; Lodges Appeal Just Before NYSGC To Rule On ‘Improper Practices’ appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

HISA Issues Updated Withdrawal Guidance For Phenylbutazone

The Anti-Doping and Medication Control (ADMC) program has proposed enforcing the screening limit of phenylbutazone at 300 ng/mL in blood, rather than the previously established screening limit of 200 ng/mL in blood. HISA will file Guidance with the Federal Trade Commission that will implement this change in the enforcement of the screening limit. The RMTC's Scientific Advisory Committee (SAC) has been asked by industry stakeholders to review its withdrawal guidance of phenylbutazone based upon the updated proposed screening limit. Based on the updated screening limit of 300 ng/mL in blood and a single IV dose of 4.4 mg/kg, the SAC has reviewed all available data and is now recommending an updated withdrawal guidance of 72 hours for phenylbutazone. The RMTC's Withdrawal Guidance of HISA's ADMC Detection Times document will reflect those changes.

The post HISA Issues Updated Withdrawal Guidance For Phenylbutazone appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post